Deutsche Bank Aktiengesellschaft Cuts Clorox (NYSE:CLX) Price Target to $128.00

Key Points

• Deutsche Bank Aktiengesellschaft has reduced Clorox's price target from $135.00 to $128.00, maintaining a "hold" rating on the stock, indicating a potential upside of 5.35%.
• Multiple analysts have also decreased their price targets for Clorox, with Bank of America setting a new target of $125.00 and JPMorgan Chase lowering theirs to $127.00, both maintaining "neutral" ratings.
• Clorox reported a quarterly earnings per share of $2.87, significantly exceeding the consensus estimate of $2.24, along with a revenue increase of 4.5% year-over-year.

Clorox (NYSE:CLX - Get Free Report) had its price target decreased by stock analysts at Deutsche Bank Aktiengesellschaft from $135.00 to $128.00 in a report released on Monday,MarketScreener reports. The firm presently has a "hold" rating on the stock. Deutsche Bank Aktiengesellschaft's price target points to a potential upside of 5.35% from the stock's previous close.

Several other equities analysts have also recently commented on the company. Bank of America reduced their target price on Clorox from $135.00 to $125.00 and set a "neutral" rating for the company in a research report on Wednesday, October 8th. JPMorgan Chase & Co. dropped their price target on Clorox from $135.00 to $127.00 and set a "neutral" rating for the company in a research note on Friday. TD Cowen reduced their price target on Clorox from $120.00 to $117.00 and set a "hold" rating on the stock in a research note on Wednesday, October 1st. Barclays cut their price objective on shares of Clorox from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Tuesday, September 30th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Clorox in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus target price of $131.64.

Clorox Stock Performance

NYSE:CLX opened at $121.51 on Monday. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. Clorox has a fifty-two week low of $116.53 and a fifty-two week high of $171.37. The company has a market cap of $14.80 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 0.98 and a beta of 0.52. The stock has a fifty day moving average price of $122.21 and a 200-day moving average price of $128.57.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same period in the previous year, the business earned $1.82 earnings per share. The company's revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, equities analysts anticipate that Clorox will post 7.15 EPS for the current fiscal year.

Insider Activity

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares of the company's stock, valued at $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.57% of the stock is currently owned by insiders.

Institutional Trading of Clorox

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in shares of Clorox by 0.6% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock valued at $1,953,000 after buying an additional 73 shares during the last quarter. Horizon Investments LLC lifted its position in shares of Clorox by 4.4% during the first quarter. Horizon Investments LLC now owns 1,768 shares of the company's stock worth $258,000 after purchasing an additional 75 shares during the last quarter. Sfmg LLC boosted its stake in shares of Clorox by 2.8% during the first quarter. Sfmg LLC now owns 2,780 shares of the company's stock valued at $409,000 after purchasing an additional 76 shares during the period. Hancock Whitney Corp lifted its holdings in Clorox by 4.3% during the 1st quarter. Hancock Whitney Corp now owns 2,064 shares of the company's stock valued at $304,000 after buying an additional 86 shares in the last quarter. Finally, American National Bank & Trust raised its stake in shares of Clorox by 69.5% during the second quarter. American National Bank & Trust now owns 217 shares of the company's stock valued at $26,000 after acquiring an additional 89 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.